The combination of tamoxifen and 9cis retinoic acid exerts overadditive anti-tumoral efficacy in rat hepatocellular carcinoma

Journal of Hepatology

Volumn 40, Issue 6, 2004, Pages 952-956

  Ganslmayer, Marion ^a   Ocker, Matthias ^a   Kraemer, Gabi ^a   Zopf, Steffen ^a   Hahn, Eckhart G ^a   Schuppan, Detlef ^a   Herold, Christoph ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Apoptosis; Hepatocellular carcinoma; Retinoic acid; Tamoxifen

Indexed keywords

ALITRETINOIN; ANTINEOPLASTIC AGENT; BROXURIDINE; TAMOXIFEN;

ADD ON THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FLOW CYTOMETRY; HEPATOMA CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; METASTASIS; MONOTHERAPY; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; DNA REPLICATION; IN SITU NICK-END LABELING; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED BUF; TAMOXIFEN; TRETINOIN;

EID: 2442638719     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(04)00057-1     Document Type: Article

References (23)

1. Herold C., Reck T., Fischler P., Ott R., Radespiel-Troeger M., Ganslmayer M., et al. Prognosis of a large cohort of paients with hepatocellular carcinoma in a single european center. Liver. 22:2002;23-28
2. Llovet J.M., Bruix G. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 37:2003;429-442
3. De Maio M., De Maio E., Perrone F., Pignata S., Daniele B. Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol. 35:2002;S109-S114
4. Stewart L.V., Thomas M.L. Retinoids differentially regulate the proliferation of colon cancer cell lines. Exp Cell Res. 233:1997;321-329
5. Hansen L.A., Sigman C.C., Andreola F., Ross S.A., Kelloff G.J., de Luca L.M. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis. 21:2000;1271-1279
6. Zhang D., Holmes W.F., Wu S., Soprano D.R., Soprano K.J. Retinoids and ovarian cancer. J Cell Physiol. 185:2000;1-20
7. Herold C., Ganslmayer M., Ocker M., Hahn E.G., Schuppan D. Combined in vitro anti-tumoral action of tamoxifen and retinoic acid derivatives in hepatoma cells. Int J Oncol. 20:2002;89-96
8. Muto Y., Moriwaki H., Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med. 340:1999;1046-1047
9. Anzano M.A., Byers S.W., Smith J.M. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. 54:1994;4614-4617
10. Blackwell K.L., Haroon Z.A., Shan S., Saito W., Broadwater G., Greenberg C.S., et al. Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res. 6:2000;4359-4364
11. El Etreby M.F., Ling Y., Lewis R.W. Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture. Prostate. 43:2000;31-42
12. Perrone F., Gallo C., Daniele B., Gaeta G.B., Izzo F., Capuano G., et al. Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial. Curr Pharm Des. 8:2002;1013-1019
13. Cheng A.L., Chen Y.C., Yeh K.H., Chuang S.E., Chen B.R., Chen D.S. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cancer. 77:1996;872-877
14. Clark J.D., Gebhart G.F., Gonder J.C., Keeling M.E., Kohn D.F. Special report: the 1996 guide for the care and use of laboratory animals. ILAR J. 38:1997;41-48
15. Kazyoshi T., Kazuki I., Susumu O. Roxatidine and cimetidine indudces angiogenesis inhibitone suppresses gropwht of clon cancer implants in syngeneic mice. J Pharmacol Sci. 93:2003;321-330
16. Qian J., Truebenbach J., Graepler F., Pereira P., Huppert P., Eul T., et al. Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma. World J Gastroenterol. 9:2003;94-98
17. Gong Y., Zhang M., Minuk G. Regulation of transforming growth factor-beta1 gene expression and cell proliferation in human hepatocellular carcinoma cells (PLC/PRF/5) by tamoxifen. J Lab Clin Med. 134:1999;90-95
18. Chow P.K., Tai B.C., Tan C.K., Machin D., Win K.M., Johnson P.J., et al. The Asian-Pacific Hepatocellular Carcinoma Trials. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomised controlled trial. Hepatology. 36:2002;1221-1226
19. Ellis C.N., Krach K.J. Uses and complications of isotretinoin therapy. J Am Acad Dermatol. 45:2000;S150-S157
20. Matsushima-Nishiwaki R., Okuno M., Adachi S., Sano T., Akita K., Moriwaki H., et al. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res. 61:2001;7675-7682
21. Fontana J.A. Interaction of retinoids and tamoxifen on the inhibition of human mammary cell proliferation. Exp Cell Biol. 55:1987;136-144
22. McKenna N.J., O'Malley B.W. Nuclear receptors, coregulators, ligands, and selective receptor modulators: making sense of the patchwork quilt. Ann NY Acad Sci. 949:2001;3-5
23. Lawrence J.A., Adamson P.C., Caruso R., Chow C., Kleiner D., Murphy R.F., et al. Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic and biomoarker evaluation. J Clin Oncol. 19:2001;2754-2763